These inflammatory cytokines and chemokines are increasingly expressed in IBD patients and are known to play an important role in the pathology of IBD.(13) Furthermore, it has been reported that activation of NF-κB is involved in the regulation of expression of these inflammatory mediators.(9,24) In this study, it is suggested that bortezomib inhibited the expression of inflammatory mediators by inhibiting activation of NF-κB in colon epithelial cells. This evidence concerns the gene NFKB1 and inflammatory bowel disease.